Frequently Asked Questions
Factors such as increasing prevalence of different forms of metastatic cancers and increase in oral drugs are acting as the major drivers for the global metastatic solid tumors market.
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India).
North America dominates the market due to the latest technology development and the presence of a variety of innovative drug molecules to enhance the treatment procedure.
Asia-Pacific is expected to have the highest market growth due to the increased prevalence of cancer and related disorders and the number of generic drugs.
